Jianzhijia Pharmaceutical Chain Group Co., Ltd. (SHA:605266)
China · Delayed Price · Currency is CNY 20.50
-0.03 (-0.15%)
At close: Feb 27, 2026
SHA:605266 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Operating Revenue | 8,460 | 8,646 | 8,537 | 7,062 | 4,863 | 4,225 |
Other Revenue | 636.61 | 636.61 | 543.85 | 452.91 | 371.79 | 241.56 |
| 9,097 | 9,283 | 9,081 | 7,514 | 5,235 | 4,466 | |
Revenue Growth (YoY) | -2.36% | 2.23% | 20.84% | 43.54% | 17.21% | 26.58% |
Cost of Revenue | 5,878 | 5,993 | 5,845 | 4,829 | 3,373 | 2,976 |
Gross Profit | 3,219 | 3,290 | 3,236 | 2,685 | 1,862 | 1,490 |
Selling, General & Admin | 2,880 | 2,938 | 2,588 | 2,121 | 1,478 | 1,188 |
Other Operating Expenses | 12.26 | 26.11 | 10.64 | 13.46 | -3.22 | 8.24 |
Operating Expenses | 2,898 | 2,965 | 2,596 | 2,139 | 1,475 | 1,196 |
Operating Income | 320.45 | 324.7 | 639.62 | 546.65 | 386.78 | 293.56 |
Interest Expense | -123.86 | -135.37 | -121.23 | -99.92 | -49.8 | -4.51 |
Interest & Investment Income | 3.68 | 5.75 | 7.04 | 7.77 | 13.67 | 3.11 |
Currency Exchange Gain (Loss) | -0.1 | -0.1 | - | - | - | -0.01 |
Other Non Operating Income (Expenses) | -6.89 | -11.35 | -12.52 | -9.14 | -6.99 | -14.9 |
EBT Excluding Unusual Items | 193.27 | 183.62 | 512.91 | 445.36 | 343.66 | 277.25 |
Impairment of Goodwill | -11.01 | -11.01 | -4.77 | -4.64 | - | - |
Gain (Loss) on Sale of Investments | -7.64 | -9.1 | -7.94 | - | - | - |
Gain (Loss) on Sale of Assets | -1.65 | 7.26 | 9.85 | -1.09 | 0.19 | -0.64 |
Asset Writedown | -3.45 | - | - | - | - | - |
Other Unusual Items | -5.19 | -1.82 | 12.64 | 1.1 | 14.38 | 23.89 |
Pretax Income | 164.33 | 168.95 | 522.7 | 440.74 | 358.23 | 300.5 |
Income Tax Expense | 34.17 | 40.99 | 108.21 | 66.28 | 58.97 | 51.09 |
Earnings From Continuing Operations | 130.16 | 127.96 | 414.49 | 374.46 | 299.26 | 249.41 |
Minority Interest in Earnings | -2.26 | 0.17 | -0.07 | -0.17 | 1.27 | 1.74 |
Net Income | 127.9 | 128.13 | 414.41 | 374.29 | 300.53 | 251.15 |
Net Income to Common | 127.9 | 128.13 | 414.41 | 374.29 | 300.53 | 251.15 |
Net Income Growth | -45.99% | -69.08% | 10.72% | 24.55% | 19.66% | 49.39% |
Shares Outstanding (Basic) | 154 | 154 | 154 | 151 | 140 | 115 |
Shares Outstanding (Diluted) | 154 | 154 | 155 | 152 | 140 | 115 |
Shares Change (YoY) | -0.55% | -0.17% | 1.91% | 8.55% | 21.58% | 9.73% |
EPS (Basic) | 0.83 | 0.83 | 2.69 | 2.48 | 2.15 | 2.18 |
EPS (Diluted) | 0.83 | 0.83 | 2.68 | 2.47 | 2.15 | 2.18 |
EPS Growth | -45.69% | -69.03% | 8.65% | 14.74% | -1.58% | 36.14% |
Free Cash Flow | 655.04 | 241.05 | 724.37 | 409.93 | 358.87 | 183.57 |
Free Cash Flow Per Share | 4.25 | 1.56 | 4.68 | 2.70 | 2.57 | 1.60 |
Dividend Per Share | 1.100 | 1.100 | 1.071 | 0.936 | 0.777 | 0.872 |
Dividend Growth | 2.73% | 2.73% | 14.41% | 20.51% | -10.98% | - |
Gross Margin | 35.38% | 35.44% | 35.64% | 35.73% | 35.57% | 33.36% |
Operating Margin | 3.52% | 3.50% | 7.04% | 7.27% | 7.39% | 6.57% |
Profit Margin | 1.41% | 1.38% | 4.56% | 4.98% | 5.74% | 5.62% |
Free Cash Flow Margin | 7.20% | 2.60% | 7.98% | 5.46% | 6.86% | 4.11% |
EBITDA | 390.46 | 393.74 | 707.38 | 599.54 | 417.79 | 318.87 |
EBITDA Margin | 4.29% | 4.24% | 7.79% | 7.98% | 7.98% | 7.14% |
D&A For EBITDA | 70.01 | 69.05 | 67.76 | 52.89 | 31.01 | 25.32 |
EBIT | 320.45 | 324.7 | 639.62 | 546.65 | 386.78 | 293.56 |
EBIT Margin | 3.52% | 3.50% | 7.04% | 7.27% | 7.39% | 6.57% |
Effective Tax Rate | 20.79% | 24.26% | 20.70% | 15.04% | 16.46% | 17.00% |
Revenue as Reported | 9,097 | 9,283 | 9,081 | 7,514 | 5,235 | 4,466 |
Advertising Expenses | - | 28.62 | 25.6 | 23.17 | 18.16 | 15.13 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.